Marshall Wace LLP Invests $192,000 in Protalix BioTherapeutics, Inc. (NYSE:PLX)

Marshall Wace LLP purchased a new position in shares of Protalix BioTherapeutics, Inc. (NYSE:PLX - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 101,899 shares of the company's stock, valued at approximately $192,000. Marshall Wace LLP owned approximately 0.14% of Protalix BioTherapeutics at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of PLX. Y Intercept Hong Kong Ltd bought a new position in Protalix BioTherapeutics during the fourth quarter worth about $35,000. PFG Investments LLC bought a new position in Protalix BioTherapeutics during the 4th quarter worth $39,000. Virtu Financial LLC acquired a new stake in shares of Protalix BioTherapeutics during the third quarter worth $44,000. Prudential Financial Inc. bought a new stake in Protalix BioTherapeutics in the 4th quarter valued at about $68,000. Finally, Renaissance Technologies LLC grew its position in shares of Protalix BioTherapeutics by 17.0% during the 4th quarter. Renaissance Technologies LLC now owns 1,118,000 shares of the company's stock worth $2,102,000 after purchasing an additional 162,100 shares in the last quarter. 16.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts recently issued reports on PLX shares. HC Wainwright boosted their price target on Protalix BioTherapeutics from $10.00 to $15.00 and gave the company a "buy" rating in a research note on Monday, February 3rd. StockNews.com lowered Protalix BioTherapeutics from a "strong-buy" rating to a "buy" rating in a report on Thursday, March 20th.

Protalix BioTherapeutics Stock Down 40.5 %

Shares of PLX stock traded down $1.17 during trading hours on Friday, reaching $1.72. The company's stock had a trading volume of 5,945,414 shares, compared to its average volume of 501,484. Protalix BioTherapeutics, Inc. has a fifty-two week low of $0.82 and a fifty-two week high of $3.10. The company has a market capitalization of $136.77 million, a price-to-earnings ratio of -13.23 and a beta of -0.05. The firm's 50 day simple moving average is $2.55 and its 200-day simple moving average is $2.14.

Protalix BioTherapeutics (NYSE:PLX - Get Free Report) last released its quarterly earnings data on Friday, May 9th. The company reported ($0.05) earnings per share for the quarter. Protalix BioTherapeutics had a negative net margin of 21.03% and a negative return on equity of 30.89%. Sell-side analysts predict that Protalix BioTherapeutics, Inc. will post 0.01 earnings per share for the current year.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.